Top-Rated StocksTop-RatedNASDAQ:VERA Vera Therapeutics (VERA) Stock Price, News & Analysis $39.89 -0.10 (-0.25%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Vera Therapeutics Stock (NASDAQ:VERA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vera Therapeutics alerts:Sign Up Key Stats Today's Range$39.50▼$40.3150-Day Range$35.66▼$46.7152-Week Range$9.24▼$50.78Volume509,030 shsAverage Volume889,666 shsMarket Capitalization$2.19 billionP/E RatioN/ADividend YieldN/APrice Target$52.67Consensus RatingBuy Company OverviewVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.Read More… Crypto’s next big bull run? (Ad)Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …And one special coin could do even better. Vera Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks58th Percentile Overall ScoreVERA MarketRank™: Vera Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 520th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingVera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVera Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Vera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.57) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vera Therapeutics is -18.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vera Therapeutics is -18.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVera Therapeutics has a P/B Ratio of 20.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vera Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.85% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Vera Therapeutics has recently decreased by 4.49%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVera Therapeutics does not currently pay a dividend.Dividend GrowthVera Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.85% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Vera Therapeutics has recently decreased by 4.49%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News Sentiment0.97 News SentimentVera Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Vera Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,873,156.00 in company stock.Percentage Held by Insiders21.70% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vera Therapeutics' insider trading history. Receive VERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VERA Stock News HeadlinesVera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 15,625 SharesOctober 12, 2024 | insidertrades.comInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells 23,125 Shares of StockSeptember 28, 2024 | insidertrades.comThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. October 17, 2024 | Porter & Company (Ad)Vera Therapeutics, Inc. (NASDAQ:VERA) Director Sells $49,445.77 in StockSeptember 21, 2024 | insidertrades.comScotiabank Initiates Coverage of Vera Therapeutics (VERA) with Sector Outperform RecommendationOctober 17 at 5:46 PM | msn.comInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells 15,625 Shares of StockOctober 14 at 4:20 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Rating of "Buy" by BrokeragesOctober 13, 2024 | americanbankingnews.comVera: Potential First Of Atacicept As A B-Cell Modulator For IgAN PatientsOctober 5, 2024 | seekingalpha.comSee More Headlines VERA Stock Analysis - Frequently Asked Questions How have VERA shares performed this year? Vera Therapeutics' stock was trading at $15.38 at the beginning of 2024. Since then, VERA shares have increased by 159.4% and is now trading at $39.89. View the best growth stocks for 2024 here. How were Vera Therapeutics' earnings last quarter? Vera Therapeutics, Inc. (NASDAQ:VERA) posted its quarterly earnings data on Thursday, August, 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.06. When did Vera Therapeutics IPO? Vera Therapeutics (VERA) raised $66 million in an initial public offering (IPO) on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO. Who are Vera Therapeutics' major shareholders? Top institutional investors of Vera Therapeutics include Handelsbanken Fonder AB (0.03%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Commodore Capital Lp, Sofinnova Venture Partners X,, Carlyle Group Inc, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Joanne Curley and Celia Lin. View institutional ownership trends. How do I buy shares of Vera Therapeutics? Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VERA CUSIPN/A CIK1831828 Webveratx.com Phone650-770-0077FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$52.67 High Stock Price Target$107.00 Low Stock Price Target$25.00 Potential Upside/Downside+32.0%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.57% Return on Assets-36.94% Debt Debt-to-Equity Ratio0.15 Current Ratio21.43 Quick Ratio21.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book20.56Miscellaneous Outstanding Shares54,830,000Free Float42,930,000Market Cap$2.19 billion OptionableOptionable Beta1.00 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:VERA) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.